Dermata Therapeutics Inc. (NASDAQ:DRMA) Stock Takes a Hit: Slumps 30% After Quarterly Earnings
Dermata Therapeutics Inc. (NASDAQ: DRMA) fell 30% after announcing its financial results for Q3 2021 and recent corporate updates.The company’s CEO Gerry Proehl said that Q3 2021 was a transformation as the company closed its IPO, made progress in the clinical pipeline for various indications, and enhanced the Board of Directors and executive team. Trading Data On Friday, DRMA stock slumped 30% at $3.31 with more 912K shares, compared to…